PremiumRatingsIO Biotech: Promising Future with Strong Clinical Progress and Financial Backing Optimistic Outlook on IO Biotech: Promising Cancer Treatment Developments and Strategic Growth Moves IO Biotech price target raised to $14 from $12 at H.C. Wainwright PremiumRatingsPromising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating IO Biotech Advances Phase 3 Trial and Secures Financing IO Biotech announces publication of preclinical data on IO112 PremiumThe FlyIO Biotech sees cash runway into 4Q25 IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA IO Biotech price target raised to $6 from $4 at Morgan Stanley 
